The Most Studied Eye Vitamin Brand†

†Based on the AREDS and AREDS2 clinical studies

Explore the history of the Age-Related Eye Disease Studies, a series of clinical studies that Bausch + Lomb collaborated with the National Eye Institute to conduct.

The AREDS Story

Age-Related Eye Disease Studies Began

  • 1992

    Government researchers at the National Eye Institute (NEI) began a study called the Age-Related Eye Disease Study to see if certain nutrients could reduce the risk of AMD progression.

  • 1995

    Bausch + Lomb started collaborating with the NEI in the AREDS studies.

  • 2001

    NEI researchers concluded the first 5-year period of the study

    • 19%

      reduced risk of moderate vision loss after five years

    • 25%

      reduction in risk of AMD progression in those with moderate-to-advanced AMD

  • 2013

    Based on new learnings around AMD, the NEI researchers decided to do more research to improve the original AREDS formula.

    • 18%

      reduced risk of progressing to advanced AMD, compared to patients taking the original AREDS formulation.

  • 2021

    NEI confirmed the formula's persistent benefits based on the 10-year AREDS2 follow-on study. During the last 5 years of the study, participants took PreserVision which was donated by Bausch + Lomb.

  • Today

    The NEI recommends the AREDS 2 nutrient formula for helping reduce the risk of progression in moderate-to-advanced AMD.